Sarepta Therapeutics (NASDAQ:SRPT) Receives Outperform Rating from Raymond James
Raymond James restated their outperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a report released on Thursday morning, Marketbeat Ratings reports. They currently have a $150.00 price objective on the biotechnology company’s stock. Other research analysts also recently issued reports about the stock. Piper Sandler lowered their price objective on shares […]
More Stories
Sanmina (NASDAQ:SANM) Stock Rating Upgraded by StockNews.com
StockNews.com upgraded shares of Sanmina (NASDAQ:SANM – Free Report) from a hold rating to a buy rating in a report...
Koshinski Asset Management Inc. Sells 626 Shares of SPDR Blackstone Senior Loan ETF (NYSEARCA:SRLN)
Koshinski Asset Management Inc. trimmed its position in SPDR Blackstone Senior Loan ETF (NYSEARCA:SRLN – Free Report) by 2.4% in...
Koshinski Asset Management Inc. Boosts Stock Position in iShares U.S. Utilities ETF (NYSEARCA:IDU)
Koshinski Asset Management Inc. increased its position in iShares U.S. Utilities ETF (NYSEARCA:IDU – Free Report) by 3.8% in the...
Koshinski Asset Management Inc. Sells 1,057 Shares of Janus Henderson Short Duration Income ETF (NYSEARCA:VNLA)
Koshinski Asset Management Inc. trimmed its holdings in shares of Janus Henderson Short Duration Income ETF (NYSEARCA:VNLA – Free Report)...
Koshinski Asset Management Inc. Has $1.22 Million Holdings in Ecolab Inc. (NYSE:ECL)
Koshinski Asset Management Inc. lowered its holdings in Ecolab Inc. (NYSE:ECL – Free Report) by 4.1% in the third quarter,...
Koshinski Asset Management Inc. Raises Position in Global X U.S. Infrastructure Development ETF (BATS:PAVE)
Koshinski Asset Management Inc. increased its position in shares of Global X U.S. Infrastructure Development ETF (BATS:PAVE – Free Report)...